HC Wainwright reaffirmed their buy rating on shares of Alpha Tau Medical (NASDAQ:DRTS – Free Report) in a research report report published on Tuesday, Benzinga reports. The brokerage currently has a $9.00 price objective on the stock. HC Wainwright also issued estimates for Alpha Tau Medical’s FY2024 earnings at ($0.47) EPS.
Separately, Piper Sandler restated an overweight rating and issued a $7.00 price target on shares of Alpha Tau Medical in a research report on Thursday, August 15th.
Get Our Latest Research Report on DRTS
Alpha Tau Medical Stock Down 1.3 %
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Levin Capital Strategies L.P. lifted its holdings in Alpha Tau Medical by 2.6% during the first quarter. Levin Capital Strategies L.P. now owns 338,764 shares of the company’s stock worth $999,000 after acquiring an additional 8,641 shares in the last quarter. Aptus Capital Advisors LLC lifted its holdings in Alpha Tau Medical by 83.7% during the second quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company’s stock worth $56,000 after acquiring an additional 10,000 shares in the last quarter. Financial Guidance Group Inc. lifted its holdings in Alpha Tau Medical by 83.7% during the second quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company’s stock worth $56,000 after acquiring an additional 10,000 shares in the last quarter. USAdvisors Wealth Management LLC bought a new position in Alpha Tau Medical during the first quarter worth about $30,000. Finally, Caprock Group LLC bought a new position in Alpha Tau Medical during the second quarter worth about $59,000. 2.65% of the stock is currently owned by institutional investors.
Alpha Tau Medical Company Profile
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
Recommended Stories
- Five stocks we like better than Alpha Tau Medical
- What are earnings reports?
- Lumen: Among Top Performers Last Month, Still Has Warning Signs
- Election Stocks: How Elections Affect the Stock Market
- Baidu’s Strong Quarter Proves a Smart Pick for Michael Burry
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.